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Abstract. 
 
Peptide growth factors control diverse cellu-
lar functions by regulating distinct signal transduction
pathways. In cultured myoblasts, insulin-like growth fac-
tors (IGFs) stimulate differentiation and promote hy-
pertrophy. IGFs also maintain muscle cell viability. We
previously described C2 skeletal muscle lines lacking ex-
pression of IGF-II. These cells did not differentiate, but
underwent progressive apoptotic death when incubated
in differentiation medium. Viability could be sustained
 
and differentiation enabled by IGF analogues that
activated the IGF-I receptor; survival was dependent
on stimulation of phosphatidylinositol 3-kinase (PI3-
kinase). We now ﬁnd that IGF action promotes myo-
blast survival through two distinguishable PI3-kinase–
regulated pathways that culminate in expression of the
cyclin-dependent kinase inhibitor, p21. Incubation with
IGF-I or transfection with active PI3-kinase led to rapid
induction of MyoD and p21, and forced expression of ei-
ther protein maintained viability in the absence of
growth factors. Ectopic expression of MyoD induced
p21, and inhibition of p21 blocked MyoD-mediated sur-
vival, thus deﬁning one PI3-kinase–dependent pathway
as leading ﬁrst to MyoD, and then to p21 and survival.
Unexpectedly, loss of MyoD expression did not impede
IGF-mediated survival, revealing a second pathway in-
volving activation by PI3-kinase of Akt, and subsequent
induction of p21. Since inhibition of p21 caused death
even in the presence of IGF-I, these results establish a
central role for p21 as a survival factor for muscle cells.
Our observations also deﬁne a MyoD-independent
pathway for regulating p21 in muscle, and demonstrate
that distinct mechanisms help ensure appropriate ex-
pression of this key protein during differentiation. 
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Introduction
 
The insulin-like growth factors (IGFs),
 
1
 
 IGF-I and IGF–II,
comprise with insulin a structurally related family of pep-
tides of fundamental importance for normal somatic
growth, for intermediary metabolism, and for the survival,
proliferation, and terminal differentiation of many differ-
ent cell types (Jones and Clemmons, 1995; Stewart and
Rotwein, 1996a; Baserga et al., 1997). The biological ef-
 
fects of these proteins are mediated by a pair of related
 
receptors. Both the IGF-I and insulin receptors are
heterotetrameric, membrane-spanning, tyrosine protein
kinases that activate a number of shared intracellular sig-
nal transduction pathways upon ligand binding (LeRoith
et al., 1995; Virkamaki et al., 1999). Insulin functions pri-
marily as a hormone of intermediary metabolism, being
synthesized in the beta cells of the endocrine pancreas,
and reaching its sites of action in liver, muscle, fat, and
other cell types through the circulation (Virkamaki et al.,
1999). By contrast, IGFs function primarily as growth, sur-
vival, and differentiation factors, and reach target tissues
through the circulation, or through local synthesis near
sites of action (Jones and Clemmons, 1995; Stewart and
Rotwein, 1996a).
 
IGF action plays key roles in the formation and mainte-
 
nance of skeletal muscle. Mice engineered to lack the IGF-I
receptor, or deficient in IGF-I and IGF-II, exhibit marked
muscle hypoplasia and die in the neonatal period because
of inadequate muscle mass to inflate their lungs (Liu et al.,
1993; Powell-Braxton et al., 1993). Conversely, mice with
enhanced expression of IGF-I in muscle develop enlarged
myofibers (Coleman et al., 1995; Barton-Davis et al., 1998).
In cultured skeletal muscle, activation of the IGF-I recep-
tor stimulates terminal differentiation through an autocrine
pathway dependent on expression of IGF-II (Florini et al.,
1991; Montarras et al., 1996; Tollefsen et al., 1989a,b). En-
dogenously produced IGF-II also plays an important role
in maintaining cell survival during the transition from pro-
liferating to terminally differentiating myoblasts (Stewart
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and Rotwein, 1996b; Lawlor et al., 2000). The signal trans-
duction pathways and mechanisms involved in IGF-medi-
ated muscle cell survival and differentiation have not been
completely elucidated. Recent studies have indicated that
two classes of intracellular signaling molecules, phosphati-
dylinositol 3-kinase (PI3-kinase) and mitogen-activated
protein kinases, are involved in muscle differentiation
(Kaliman et al., 1996, 1998; Bennett and Tonks, 1997; Cool-
ican et al., 1997; Sarbassov et al., 1997; Gredinger et al.,
1998; Jiang et al., 1998; Sarbassov and Peterson, 1998;
Cuenda and Cohen, 1999; Musaro and Rosenthal, 1999;
Rommel et al., 1999; Zetser et al., 1999; Tamir and Bengal,
2000; Wu et al., 2000), with the PI3-kinase pathway being
considered more critical. At present, the mechanisms have
not been established by which these signaling molecules or
other pathways activated by the IGF-I receptor might col-
laborate with myogenic regulatory factors to regulate mus-
cle cell viability or differentiation.
The muscle-specific basic helix-loop-helix (bHLH) tran-
scription factors, MyoD, myogenin, MRF4, and Myf5, were
initially identified as master regulators of cell fate because
of their ability to confer a skeletal muscle phenotype on
nonmuscle cells (Weintraub, 1993; Olson and Klein, 1994).
These proteins function by activating genes that are re-
quired for muscle determination and/or differentiation
through the formation of heterodimers with ubiquitous
bHLH proteins, and subsequent binding to specific se-
quences termed E boxes in the promoter-regulatory re-
gions of muscle-restricted target genes (Weintraub, 1993;
Olson and Klein, 1994). One of the targets of MyoD is the
gene encoding the cyclin-dependent protein kinase inhibi-
tor, p21, also known as Waf1 and Cip1 (Ball, 1997; El-
Deiry, 1998). This protein, and related molecules, p27/Kip1
and p57/Kip2 (Ball, 1997), act to block progression through
the cell cycle by reversibly inhibiting complexes of several
different cyclins and cyclin-dependent kinases (Elledge,
1996). In cultured muscle cells, p21 expression is induced
as an early event during differentiation (Guo et al., 1995;
Halevy et al., 1995; Parker et al., 1995; Mal et al., 2000).
The increase in p21 is temporally associated with an ongo-
ing decline in cyclin-dependent kinase activity as differenti-
ation proceeds (Guo et al., 1995; Mal et al., 2000), and p21
has been found to become part of a complex containing cy-
clin E and cdk2 in differentiating C2 muscle cells (Mal et
al., 2000). In addition, induction of p21 has been shown to
correlate with development of an apoptosis-resistant phe-
notype during differentiation (Wang and Walsh, 1996).
The significance of p21 action in skeletal muscle is under-
scored by observations that high levels of p21 mRNA are
detected in early muscle fibers in the mouse embryo
(Parker et al., 1995), and that mice deficient in both p21
and p57 have defective muscle formation and exhibit in-
creased rates of myoblast apoptosis (Zhang et al., 1999). It
generally has been accepted that MyoD is a key transcrip-
tion factor regulating p21 gene expression during muscle
differentiation. MyoD has been found to enhance activity
of the p21 promoter in transient transfection experiments
(Halevy et al., 1995), and to stimulate p21 mRNA and pro-
tein accumulation in muscle cells and fibroblasts (Guo et
al., 1995; Halevy et al., 1995; Parker et al., 1995), including
cells lacking p53, the tumor suppressor protein that also
can activate the p21 gene (Halevy et al., 1995).
 
In this manuscript, we address the question of how IGF
action promotes muscle cell survival through study of C2
myoblasts and a derived cell line that lacks expression of
IGF-II (Stewart and Rotwein, 1996b). These cells undergo
rapid apoptotic death when incubated in low serum differ-
entiation medium (Stewart and Rotwein, 1996b; Lawlor et
al., 2000; Lawlor and Rotwein, 2000). Addition of IGF-I or
analogues that activate the IGF-I receptor maintain cell
viability, but this is reversed by inhibitors of PI3-kinase
(Lawlor et al., 2000). We now find that IGF action pro-
motes myoblast survival by two different PI3-kinase–
dependent pathways that converge on p21. Incubation
with IGF-I, or transfection with active PI3-kinase, leads to
rapid induction of MyoD and p21, and ectopic expression
of either protein sustains muscle cell survival in the ab-
sence of growth factors. Forced expression of MyoD in-
duces p21, and inhibition of p21 expression blocks MyoD-
mediated survival, thus defining one pathway as leading
through PI3-kinase to MyoD, and then to p21 and sur-
vival. The second IGF-stimulated pathway involves activa-
tion of the serine-threonine kinase, Akt, a protein that has
been shown to play a key role in the survival of many dif-
ferent cell types (Datta et al., 1999). We find that Akt in-
duces p21 in myoblasts by a mechanism that does not re-
quire MyoD. Since inhibition of p21 causes apoptotic
death even in the presence of IGF-I, our results establish a
central role for p21 as a survival factor for muscle cells,
and demonstrate that distinct but integrated mechanisms
help ensure the appropriate expression of this key protein
during myogenic differentiation.
 
Materials and Methods
 
Materials
 
Fetal calf serum, newborn calf serum, horse serum, Dulbecco’s modified
Eagle’s medium, phosphate buffered saline, G418, PDGF-BB, and TRIzol
were purchased from Life Technologies. The long-lasting IGF-I analogue,
R
 
3
 
IGF-I, was from Gro
 
pep
 
. Effectene was purchased from QIAGEN. Re-
striction enzymes, ligases, and polymerases were from New England Bio-
labs. The pEGFP-N3 plasmid was purchased from CLONTECH Labora-
tories, Inc. Protease inhibitor tablets were from Roche Molecular
Biochemicals. The BCA protein assay kit was from Pierce Chemical Co.
Antibodies to p21 and CDK-4 used for immunoblotting were purchased
from Santa Cruz Biotechnology, Inc. The antibody to MyoD was a gift
from Dr. Peter J. Houghton (St. Jude Children’s Research Hospital,
Memphis, TN). Secondary antibodies were from Sigma-Aldrich. Antibod-
ies to MyoD and p21 used for immunocytochemistry were obtained from
Santa Cruz Biotechnology, Inc. and PharMingen, respectively. The anti-
body to influenza hemagglutinin (HA) was from BabCO, and the anti–
myc antibody (clone 9E-10) was from the Developmental Studies Hy-
bridoma Bank (University of Iowa, Iowa City, IA). Secondary antibodies
conjugated to fluorophores were purchased from Molecular Probes. Ni-
trocellulose was from Schleicher & Schuell, and ECL reagents from Am-
ersham-Pharmacia Biotech. X-ray film was purchased from Eastman
Kodak Co. All other chemicals were reagent grade.
 
Cell Culture
 
C2 myoblasts stably transfected with the coding region of a mouse IGF-II
cDNA in the antisense orientation (C2AS12 cells; Stewart and Rotwein,
1996b; Lawlor et al., 2000) were grown until 
 
.
 
95% confluent on gela-
tin-coated tissue culture dishes in DMEM supplemented with 10% heat-
inactivated FCS, 10% heat-inactivated newborn calf serum, 2 mM 
 
L
 
-gluta-
mine, and 400 
 
m
 
g/ml G418 (active drug) (growth medium). C2 myoblasts
(Yaffe and Saxel, 1977) were grown until 
 
.
 
95% confluent on gelatin-
coated plates in growth medium minus G418. For both cell lines, differen-
tiation was initiated after washing with PBS by incubating in differentia- 
Lawlor and Rotwein 
 
Mechanisms of IGF–mediated Myoblast Survival
 
1133
 
tion medium (DM) containing DMEM plus 2% horse serum, or in DM
supplemented with 0.4 nM PDGF-BB or 2 nM R
 
3
 
IGF-I. At different in-
tervals, adherent cells were trypsinized and counted by hemocytometer or
by Coulter particle counter. Cos7 cells were grown in DMEM supple-
mented with 10% heat-inactivated FCS and 2 mM 
 
L
 
-glutamine.
 
RNA Isolation and Ribonuclease Protection Assays
 
Total RNA was isolated from cells using TRIzol and quantitated by spec-
trophotometry. RNA integrity was assessed by electrophoresis though 1%
agarose-formaldehyde gels after staining with ethidium bromide. Solution
hybridization ribonuclease protection assays were performed as described
(Stewart et al., 1996), using single stranded [
 
a
 
-
 
32
 
P]CTP-labeled antisense
riboprobes synthesized from linearized plasmid templates. Results were
quantitated with a PhosphorImager (GS 525; Bio-Rad Laboratories).
 
Protein Isolation and Immunoblotting
 
Protein extracts were isolated after washing cells twice with cold PBS by
incubating for 30 min at 4
 
8
 
C in RIPA buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 0.1% SDS, 1.0% NP-40, and 1.0% deoxycholate) containing pro-
tease inhibitors, 1 
 
m
 
M okadaic acid, and 1 
 
m
 
M sodium orthovanadate. Af-
ter removal of insoluble material by centrifugation at 14,000 rpm for 10
min at 4
 
8
 
C, protein concentration was determined by BCA assay. Protein
extracts (60 
 
m
 
g) were separated by SDS-polyacrylamide gel electrophore-
sis under denaturing and reducing conditions before transfer to 0.2 
 
m
 
M ni-
trocellulose membranes at 18 V for 45 min using a semidry blotter. Mem-
branes were blocked for 2 h at 25
 
8
 
C in TBST (Tris buffered saline plus
0.1% Tween-20) containing 5% nonfat dry milk (blocking buffer) before
being incubated with primary antibody (anti–MyoD undiluted superna-
tant, anti–p21 1:75, and anti–CDK4 1:500 in blocking buffer). After incu-
bation with horseradish peroxidase–conjugated secondary antibodies
(1:2,000 in blocking buffer), proteins were detected by ECL, followed by
exposure to x-ray film. Results were quantitated by densitometry (GS 700;
Bio-Rad Laboratories).
 
Immunocytochemistry
 
Cells were washed twice with PBS before fixation in 1% paraformalde-
hyde for 10 min. Cells were then incubated for 5 min in PBS containing
0.2% Triton X-100 (PBST), washed twice with PBST, and incubated with
primary antibodies: polyclonal rabbit anti–MyoD (1:500), polyclonal rab-
bit anti–p21 IgG (1:2,000), monoclonal anti–HA IgG (1:100), or mono-
clonal anti–myc (1:500) in PBST plus 3% bovine serum albumin for 3–16 h
at 4
 
8
 
C. Cells were washed three times with PBST before incubation with
polyclonal secondary antibodies, either Alexa 594-tagged goat anti–rabbit
IgG (1:2,000), fluorescein-conjugated goat anti–rabbit IgG, or fluorescein-
conjugated goat anti–mouse IgG (each 1:1,000), for 45 min in the dark.
Images were captured with a fluorescence microscope (Eclipse TE 300;
Nikon) and an CCD camera (Optronics) using Scion Image 1.62 software.
Images were save in Photoshop 5.5 (Adobe Systems).
 
Construction of Bicistronic Expression Plasmids
 
The internal ribosome entry site (IRES) from mouse encephalomyocardi-
tis virus (Ghattas et al., 1991) was subcloned into the polylinker of
pEGFP-N3 to generate pIRES-EGFP. An XhoI–BamHI DNA fragment
containing the coding region of murine MyoD in the sense orientation was
excised from pBluescript and subcloned 5
 
9 
 
to the IRES to generate
MyoD-IRES-EGFP. A BamHI–SalI DNA fragment containing the
mouse MyoD coding region in the antisense orientation was used to gen-
erate MyoD
 
AS
 
-IRES-EGFP. The p21-IRES-EGFP, p21
 
AS
 
-IRES-EGFP,
PI3-kinase, and iAkt plasmids have been described (Lawlor et al., 2000;
Lawlor and Rotwein, 2000).
 
Transfections
 
Myoblasts were plated at 13,000 cells/cm
 
2
 
 onto 12-well tissue culture
dishes and incubated for 24 h in growth medium. DNA-mediated gene
transfer was performed using Effectene, following the protocol of the
manufacturer. A total of 1 
 
m
 
g of DNA of sense plasmids was used per
well. For antisense plasmids [MyoD
 
AS
 
-IRES-EGFP and p21
 
AS
 
-IRES-
EGFP DNA], or control [EGFP], 2 
 
m
 
g of DNA were used, and for
cotransfections a total of 2 
 
m
 
g of DNA was added to cells. After incuba-
tion with DNA for 16–18 h, fresh growth medium was added to the cells.
When cells reached confluent density at 
 
z
 
48 h after transfection, they
 
were incubated in DM without or with growth factors for an additional 24
or 48 h. Transfection efficiencies ranged from 12–20% (C2AS12 cells) to
19–23% (C2 myoblasts). Cos 7 cells were grown in six-well dishes and
were transfected with 2 
 
m
 
g of DNA using the calcium phosphate precipita-
tion method (Stewart and Rotwein, 1996b). Expression of p21 and MyoD
was analyzed by immunoblotting.
 
Survival Assays of Transfected Cells
 
Myoblasts were transfected as described above. When cells reached con-
fluent density at 
 
z
 
48 h after transfection, two wells were harvested and
both total cell number [T
 
0(total)
 
] and transfection efficiency were assessed.
The latter value was determined by averaging the fraction of cells express-
ing EGFP in 20 hemocytometer fields at a magnification of 200
 
3
 
 [T
 
0(trans-
fected)
 
]. The remaining wells were incubated in DM without or with growth
factors for 24 or 48 h. At each interval, cells were harvested and total and
transfected cells were counted. Survival of transfected cells at 24 h was de-
termined by the following formula: % survival = [T
 
24(transfected)
 
/T
 
0(trans-
fected)
 
 
 
3
 
 (T
 
24(total)
 
/T
 
0(total)
 
] 
 
3
 
 100. Survival at 48 h was assessed similarly.
 
Statistical Analysis
 
Results are presented as the mean 
 
6
 
 SEM. Statistical significance was de-
termined using independent Student’s 
 
t
 
 test for paired samples. Results
were considered statistically significant when
 
 P 
 
,
 
 0.05.
 
Results
 
Prevention of Myoblast Death by IGF-I
 
We have shown previously that signaling through the IGF-I
receptor by endogenously produced IGF-II is essential
for myoblast survival as cells begin to differentiate (Stew-
art and Rotwein, 1996b; Lawlor et al., 2000; Lawlor and
Rotwein, 2000). As seen in Fig. 1, C2 myoblasts engi-
neered to lack IGF-II expression (C2AS12 cells) under-
went rapid death when incubated in DM. Only 48 
 
6
 
 1% of
cells remained alive after 24 h, and only 34 
 
6
 
 1% survived
after 48 h. Viability continued to decline progressively
with longer incubations in DM (Lawlor and Rotwein,
2000). Addition of IGF-I caused complete survival (102 
 
6
 
3% at 24 h, 98 
 
6
 
 4% at 48 h). Other growth factors such as
PDGF-BB also maintain viability of C2AS12 cells (Lawlor
et al., 2000, and data not shown). Nontransfected C2 myo-
blasts also underwent apoptotic death when incubated in
DM, with 
 
z
 
30% of cells dying at 24 h (see Fig. 7; and
Lawlor and Rotwein, 2000). No further death occurred
upon longer incubation in DM, with survival correlating
Figure 1. IGF-I treatment maintains myoblast survival. Results
are shown for cell counts (expressed as percent at time 0, % T0)
of C2AS12 myoblasts after a 24 or 48 h incubation in DM with or
without R3IGF-I (2 nM). Asterisks indicate that significantly
fewer cells survived (*P , 0.005, **P , 0.001) in untreated than
in growth factor–treated cells (mean 6 SEM of three experi-
ments, each performed in duplicate). 
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with expression of IGF-II (Tollefsen et al., 1989b; Lawlor
and Rotwein, 2000).
 
Stimulation of MyoD and p21 mRNA and Protein 
Expression after IGF-I Treatment
 
The results in Fig. 1 prompted investigation of mecha-
nisms of IGF-mediated muscle cell survival. The cyclin-
dependent kinase inhibitor, p21, has been found to func-
tion as a survival factor for muscle and other cell types (Poluha
et al., 1996; Wang and Walsh, 1996; Levkau et al., 1998),
and MyoD has been shown to induce p21 expression (Guo
et al., 1995; Halevy et al., 1995; Parker et al., 1995). We
thus asked whether IGF treatment stimulated expression
of MyoD or p21 in C2AS12 cells. Results of time course
studies are shown in Fig. 2. Treatment with IGF-I caused a
sustained increase in the abundance of both MyoD and
p21 mRNAs beginning at 8 h, the earliest time point exam-
ined, and lasting up to 48 h. Peak values of 7- and 10-fold
above baseline were seen at 24 h for MyoD and p21, re-
spectively. By contrast, PDGF-BB had a minimal effect.
Similar results were seen when MyoD and p21 protein ex-
pression was examined. A progressive increase was seen in
the abundance of both proteins after incubation with IGF-I,
reaching fourfold above T
 
0
 
 for MyoD and sevenfold for
p21 (mean 
 
6
 
 SEM of three experiments). PDGF caused at
best a transient rise in MyoD that returned to baseline lev-
els or below within 8 h (Fig. 2 B). Additionally, as shown
by immunocytochemistry, MyoD and p21 could be de-
tected in nearly all myoblasts after a 24-h incubation with
IGF-I, while few cells expressed either protein after treat-
ment with PDGF (Fig. 2 C). Thus, IGF-I caused a progres-
sive and sustained induction of MyoD and p21 mRNA and
protein expression in C2AS12 cells.
Figure 2. Treatment with IGF-I stimulates expression of MyoD
and p21. (A) Induction of MyoD and p21 mRNAs by IGF-I. The
autoradiographs show results of representative ribonuclease pro-
tection assays performed using total RNA isolated from C2AS12
cells incubated with either R3IGF-I (2 nM) or PDGF-BB (0.4
nM) for the indicated times (top, MyoD; middle, p21). (Bottom)
Photograph of an ethidium bromide–stained gel of the RNA
used in these studies. Similar results were seen in three indepen-
dent experiments. (B) Induction of MyoD and p21 proteins by
IGF-I. Representative immunoblots are shown using whole-cell
protein extracts from C2AS12 cells incubated with either R3IGF-I
(2 nM) or PDGF-BB (0.4 nM) for the indicated times, and anti-
bodies to MyoD (top), p21 (middle), and CDK-4 (bottom). Simi-
lar results were seen in three independent experiments. (C) Rep-
resentative fluorescence micrographs of C2AS12 myoblasts
treated with either R3IGF-I (2 nM) or PDGF-BB (0.4 nM) for
24 h, as described in Materials and Methods, and immunostained
with antibodies to MyoD (top left), or p21 (top right), and incu-
bated with Hoechst nuclear dye (bottom).
Figure 3. MyoD and p21 promote myoblast survival. (A) Expres-
sion of MyoD and p21 in transfected Cos7 cells. Cos7 cells were
transiently transfected with expression plasmids encoding MyoD-
IRES-EGFP (MyoD), p21-IRES-EGFP (p21), or EGFP alone, as
outlined in Materials and Methods. Whole-cell protein extracts
were isolated 48 h after transfection and used for immunoblotting
with antibodies to MyoD (top) or p21 (bottom). Whole-cell ex-
tracts from differentiating C2 myoblasts (C2) were used as a posi-
tive control. (B) MyoD and p21 promote muscle cell survival.
C2AS12 myoblasts were transfected with plasmids encoding either
MyoD-IRES-EGFP (MyoD), p21-IRES-EGFP (p21), or EGFP
alone. Counts of transfected cells were performed after a 24-h in-
cubation in DM without or with R3IGF-I (2 nM). Results are pre-
sented as percent survival compared with T0 (mean 6 SEM of four
experiments, each performed in duplicate). *Survival was signifi-
cantly lower in myoblasts transfected with EGFP than in cells
transfected with MyoD or p21, or treated with IGF-I (P , 0.001). 
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Forced Expression of MyoD or p21 Promotes
Myoblast Survival
 
We next asked whether MyoD or p21 could maintain mus-
cle cell survival in the absence of growth-factor treatment.
We generated bicistronic expression plasmids using cDNAs
for mouse MyoD or mouse p21, followed by a cassette
containing an IRES derived from murine encephalomyo-
carditis virus and the marker protein EGFP. C2AS12 myo-
blasts were transiently transfected with these recombinant
plasmids or with a control encoding EGFP alone, and cell
survival was measured by cell counting after 24 h in DM.
As depicted in Fig. 3, MyoD and p21 each promoted a sig-
nificant increase in myoblast viability over results ob-
tained with EGFP (MyoD: 84 
 
6
 
 5% survival; p21: 98 
 
6
 
4%; EGFP: 52 
 
6
 
 5%;
 
 P 
 
,
 
 0.001 compared with EGFP).
The latter value is similar to the 48 
 
6
 
 1% survival seen in
nontransfected myoblasts (Fig. 1). Incubation with IGF-I
 
maintained complete cell viability, indicating that neither
the recombinant plasmids nor the process of transfection
were toxic. Comparable results were obtained after 48 h in
DM (data not shown).
 
p21 Is Required for MyoD-stimulated Muscle
Cell Survival
 
Based on published studies showing that MyoD stimulated
p21 expression in muscle and fibroblasts (Guo et al., 1995;
Halevy et al., 1995; Parker et al., 1995), we anticipated that
forced expression of MyoD would promote accumulation
of endogenous p21 in our cell line. C2AS12 myoblasts
were transiently transfected with the MyoD expression
plasmid and cells were immunostained for p21 after incu-
bation for 24 h in DM. As shown in Fig. 4 A and graphed
in B, MyoD induced p21 protein expression in the major-
ity of transfected cells (75 
 
6
 
 5%), compared with only 25 
 
6
 
2% of cells transfected with EGFP (
 
P 
 
,
 
 
 
0.005), a value
similar to that seen in nontransfected myoblasts (data not
shown). To determine whether p21 was necessary for
MyoD-mediated muscle cell survival, we cotransfected
C2AS12 myoblasts with MyoD and either a p21 antisense
plasmid (p21
 
AS
 
) or a plasmid encoding EGFP. We have
shown recently that this p21
 
AS
 
 cDNA blocked IGF-induced
p21 protein expression in C2AS12 myoblasts (Lawlor and
Rotwein, 2000). Cell survival was assessed after incubation
for 24 h in DM. As seen in Fig. 4 C, MyoD was unable to
maintain muscle cell viability in the presence of the p21
 
AS
 
plasmid (30 
 
6
 
 4% survival), but could sustain viability
when cotransfected with EGFP (73 
 
6
 
 3%, 
 
P 
 
,
 
 
 
0.001).
Figure 4. p21 is required for MyoD-stimulated muscle cell sur-
vival. (A) MyoD induces p21 protein expression. C2AS12 cells
were transfected with either EGFP or MyoD-IRES-EGFP ex-
pression plasmids, and following a 24-h incubation in DM, fixed,
and stained with an antibody to p21. (Top) Expression of EGFP,
(middle) immunostaining for p21, and (bottom) nuclear staining
with Hoechst dye. (B) The graph records the percent of trans-
fected cells expressing p21. Significantly fewer cells are positive
for p21 after transfection with EGFP than with MyoD-IRES-
EGFP (*P  ,  0.005; mean 6 SEM of three experiments, 100
transfected cells counted per experiment). (C) Inhibition of p21
prevents MyoD-stimulated muscle cell survival. C2AS12 cells
were cotransfected with MyoD-IRES-EGFP (MyoD) and either
EGFP or p21AS-IRES-EGFP (p21AS), as outlined in Materials
and Methods. Cell counts of transfected myoblasts were per-
formed after a 24-h incubation in DM. Results are presented as
percent survival compared with T0 (mean 6 SEM of three exper-
iments, each performed in duplicate). *Survival was significantly
less in myoblasts cotransfected with p21AS-IRES-EGFP than
with EGFP (P , 0.014).
Figure 5. Forced expression of a MyoD antisense plasmid blocks
IGF-I–stimulated MyoD expression. (A) C2AS12 cells were
transiently transfected with the MyoDAS-IRES-EGFP expression
plasmid, as described in Materials and Methods, and incubated in
DM plus R3IGF-I (2 nM) for 24 h, followed by fixation and stain-
ing for MyoD. (Left) Expression of EGFP, (center) immu-
nostaining for MyoD, and (right) merged image. (B) The graph
indicates the percentage of transfected cells expressing MyoD, as
assessed by immunocytochemistry following IGF-I treatment.
Significantly fewer cells are positive for MyoD after transfection
with MyoDAS-IRES-EGFP than with EGFP (*P , 0.01; mean 6
SEM of three experiments, counting 100 cells per experiment). 
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These results indicate that MyoD promotes muscle cell
survival by inducing p21.
 
MyoD Is Not Required for IGF-mediated
Myoblast Survival
 
We have demonstrated that p21 is necessary for IGF-
mediated survival of C2AS12 cells and wild-type C2 and
L6 myoblasts (Lawlor and Rotwein, 2000). Since both
MyoD and p21 are induced by IGF-I, and MyoD stimu-
lates expression of p21, we next asked if MyoD was a nec-
essary component of an IGF-stimulated muscle cell sur-
vival pathway. We first tested the effectiveness of a MyoD
antisense cDNA (MyoD
 
AS
 
) to prevent IGF-stimulated
MyoD protein expression. C2AS12 cells were transiently
transfected with an expression plasmid containing a mouse
MyoD cDNA in the antisense orientation (MyoD
 
AS
 
-
IRES-EGFP), and were immunostained for MyoD after a
 
24-h incubation in DM plus IGF-I. As seen in Fig. 5, the
MyoD
 
AS
 
 plasmid caused a marked reduction in IGF-stim-
ulated expression of MyoD. MyoD was detected in only
34 
 
6
 
 2% of transfected cells, compared with 78 
 
6
 
 5% of
myoblasts transfected with EGFP (
 
P 
 
,
 
 
 
0.014).
The MyoD
 
AS
 
 plasmid did not reduce IGF-mediated
muscle cell viability. As shown in Fig. 6 A, IGF-I main-
tained complete survival of myoblasts transfected with the
MyoD
 
AS
 
 cDNA. In the absence of growth factor treat-
ment, 49 6 5% of transfected cells remained alive after a
24-h incubation in DM, a level similar to that seen in non-
transfected myoblasts (48 6 1%, see Fig. 1), and contrast-
ing with the 82 6 4% viability of cells transfected with the
MyoD sense vector (P , 0.016). In contrast with our re-
cent observations that a p21AS plasmid inhibited IGF-
mediated muscle cell survival (Lawlor and Rotwein, 2000),
forced expression of the MyoDAS plasmid did not attenu-
ate the ability of IGF-I to promote complete myoblast via-
bility (100 6 3%). These results indicate that while MyoD
can sustain muscle cell viability through p21, it is not neces-
sary for IGF-regulated myoblast survival. Based on these
observations, we next asked if IGF-I could stimulate p21
expression in cells transfected with the MyoDAS plasmid.
As shown by immunocytochemistry in Fig. 6 B, incubation
with IGF-I equivalently induced p21 in myoblasts trans-
fected with MyoDAS or EGFP (84% for MyoDAS vs. 78%
for EGFP). Thus, MyoD does not appear to be a critical
component of a survival pathway involving IGF-I and p21.
A MyoD Antisense cDNA Does Not Inhibit Survival of 
C2 Myoblasts
Parental C2 myoblasts, which produce IGF-II during differ-
entiation (Tollefsen et al., 1989b), undergo limited apoptotic
death during incubation in DM, with z70% viability over
the first 24 h, and little cell death subsequently (Lawlor and
Rotwein, 2000). We next asked if MyoD was involved in the
survival of these cells. C2 myoblasts were transfected with
the MyoDAS plasmid or with a p21AS expression construct
that we have shown diminishes C2 cell survival (Lawlor and
Rotwein, 2000). Fig. 7 demonstrates that forced expression
of MyoDAS had little effect on C2 muscle cell survival be-
Figure 6. MyoD is not required for IGF-mediated survival of
C2AS12 myoblasts. (A) C2AS12 cells were transiently trans-
fected with MyoD-IRES-EGFP or MyoDAS-IRES-EGFP expres-
sion plasmids, as described in Materials and Methods. Cell counts
of transfected myoblasts were performed after a 24-h incubation
in DM or in DM supplemented with R3IGF-I (2 nM). Results are
expressed as the mean 6 SEM of three independent experi-
ments, each performed in duplicate. **Survival was significantly
less in myoblasts transfected with MyoDAS than in cells trans-
fected with MyoD or treated with IGF-I (P , 0.001). (B) Inhibi-
tion of MyoD expression does not block IGF-mediated induction
of p21. Representative fluorescence micrographs of C2AS12 myo-
blasts transiently transfected with expression plasmids for Myo-
DAS-IRES-EGFP or EGFP alone, and treated with IGF-I (2 nM)
in DM for 24 h. (Top) Expression of EGFP, (middle) immu-
nostaining for p21, and (bottom) nuclei stained with Hoechst
dye. As determined by cell counting, z80% of cells transfected
with either plasmid expressed p21 after incubation with IGF-I.
Figure 7. Inhibition of MyoD does not block survival of C2 myo-
blasts. C2 myoblasts were transiently transfected with MyoDAS-
IRES-EGFP or p21AS-IRES-EGFP expression plasmids, as de-
scribed in Materials and Methods. Cell counts of transfected cells
were performed after a 24 or 48 h incubation in DM. Results are
expressed as the mean 6 SEM of three independent experi-
ments, each performed in duplicate. The asterisks denote that vi-
ability was significantly less in myoblasts transfected with p21AS
than in cells transfected with MyoDAS or untransfected cells
(*P , 0.003, **P , 0.00002).Lawlor and Rotwein Mechanisms of IGF–mediated Myoblast Survival 1137
yond what was seen in the nontransfected population (24 h
viability: 72 6 3% vs. 73 6 3%; 48 h viability: 70 6 2% vs.
69 6 3%, respectively, P 5 NS). By contrast, forced expres-
sion of p21AS resulted in a dramatic decrease in viability,
with 42 6 4% of transfected cells remaining alive after a 24-h
incubation in DM, and only 17 6 1% by 48 h. Taken to-
gether with results shown in Fig. 6, these observations indi-
cate that induction of p21 expression by MyoD is not a criti-
cal pathway for IGF-mediated muscle cell survival.
Differential Expression of MyoD and p21 by
IGF-activated Signaling Pathways
The results described above suggest that IGF-I induces the
expression of MyoD and p21 by distinct mechanisms. In
recent studies, we demonstrated that IGF-I treatment re-
sulted in the sustained stimulation of both PI3-kinase and
Akt kinase activities in muscle cells, and showed that a
constitutively active PI3-kinase or an inducible Akt could
maintain myoblast survival in the absence of growth fac-
tors (Lawlor et al., 2000). Based on these observations and
on the results in Fig. 2, we next asked if either signaling
molecule was involved in IGF-mediated stimulation of
MyoD or p21. Transient transfection of an active PI3-
kinase (p110*) into C2AS12 myoblasts led to the induc-
tion of MyoD and p21 in the absence of IGF-I treatment,
as determined by immunocytochemistry after a 24-h incu-
bation in DM (Fig. 8). Over 80% of cells positive for p110*
also expressed both MyoD and p21. By contrast, in cells
transfected with an inactive PI3-kinase (p110Dkin), the
level of expression of MyoD or p21 (31–36%) did not ex-
ceed values detected in nontransfected myoblasts (data
not shown). Thus, PI3-kinase can coordinately stimulate
the expression of MyoD and p21 in muscle cells.
We next examined the ability of Akt to stimulate MyoD
and p21 protein accumulation. Myoblasts were transfected
with an expression plasmid encoding hydroxytamoxifen
(HT)-inducible HA-tagged Akt (iAkt), and MyoD and
p21 were detected by immunocytochemistry after incuba-
tion for 24 h in DM without or with HT. Upon transfection
with the iAkt plasmid, Akt protein is expressed, but its en-
zymatic activity requires induction by HT (Lawlor et al.,
2000). As shown in Fig. 9 A, HT treatment had little effect
on the low level of MyoD protein accumulation observed
(36 6 2% vs. 33 6 2% without HT, P 5 NS). By contrast,
addition of HT caused a significant increase in p21 protein
expression (78 6 4% vs. 24 6 4%, P , 0.01), as demon-
strated previously (Lawlor and Rotwein, 2000). Based on
these observations, and on the results in Fig. 6, we con-
clude that IGF-activated signal transduction pathways
control muscle cell survival by at least two mechanisms,
one involving induction of MyoD mRNA and protein
Figure 8. Induction of MyoD and p21 after transfection of active
PI3-kinase. (A) Induction of MyoD by PI3-kinase. Pictured are
representative fluorescence micrographs of C2AS12 muscle cells
transiently transfected with plasmids encoding active (p110*) or
inert (p110Dkin) PI3-kinase, as described in Materials and Meth-
ods. After a 24-h incubation in DM, cells were fixed and immu-
nostained for expression of either PI-3 kinase using an antibody
directed against the c-myc epitope tag (top) or for MyoD (bot-
tom). The graph shows that the percent of transfected cells ex-
pressing MyoD was significantly less after transfection with
p110Dkin than with p110* (mean 6 SEM of three experiments,
counting 100 cells per experiment, *P , 0.01). (B) Induction of
p21 by PI3-kinase. Illustrated are representative fluorescence mi-
crographs of C2AS12 muscle cells transiently transfected with
the p110* or p110Dkin expression plasmids, as described in A.
After a 24-h incubation in DM cells were immunostained for ex-
pression of either protein (top), and for p21 (bottom). The graph
shows that the percentage of transfected cells expressing p21 was
significantly smaller after transfection with p110Dkin than with
p110* (mean 6 SEM of three experiments, counting 100 cells per
experiment, **P , 0.001).
Figure 9. Induction of p21 but not MyoD after activation of
transfected Akt. (A) Akt does not induce MyoD. Pictured are
representative fluorescence micrographs of C2AS12 cells tran-
siently transfected with hydroxytamoxifen-inducible HA-tagged
Akt (iAkt), as described in Materials and Methods. After a 24-h
incubation with DM in the absence or presence of hydroxyta-
moxifen, cells were fixed and immunostained using antibodies to
the HA tag (top) and MyoD (bottom). The graph shows that the
fraction of transfected cells expressing MyoD was not signifi-
cantly different in cells incubated without or with HT (mean 6
SEM of three experiments, counting 100 cells per experiment).
(B) Akt induces p21. Illustrated are representative fluorescence
micrographs of C2AS12 cells transiently transfected with iAkt, as
described in Materials and Methods. After a 24-h incubation in
DM without or with HT, the cells were immunostained using an-
tibodies to the HA tag (top) and to p21 (bottom). The graph
shows that the percentage of transfected cells expressing p21 was
significantly greater after incubation with HT (mean 6 SEM of
three experiments, counting 100 cells per experiment, *P , 0.01).The Journal of Cell Biology, Volume 151, 2000 1138
through PI3-kinase, with the subsequent stimulation of p21
expression, and the other through induction of p21 by Akt.
Discussion
Muscle differentiation is a multi-step process involving
permanent withdrawal from the cell cycle, expression of
muscle-specific genes and proteins, and fusion of myo-
blasts into multinucleated myotubes (Lassar et al., 1994;
Arnold and Winter, 1998). In this paper, we focus on steps
involved in control of myoblast survival during early
phases of differentiation. We show that the cyclin-depen-
dent kinase inhibitor, p21, plays a key role in maintaining
muscle cell viability and that its expression is regulated by
two interdependent, yet distinguishable pathways. One
pathway involves stimulation of MyoD expression by PI3-
kinase, and subsequent induction of p21 by MyoD; the
other involves activation of Akt by PI3-kinase, followed
by stimulation of p21 expression. Both pathways collabo-
rate to maintain survival and are connected through PI3-
kinase, which itself is required for IGF-regulated muscle
cell viability (Lawlor et al., 2000). The pathways diverge
distal to PI3-kinase, as Akt induces expression of p21 but
not MyoD, and inhibition of MyoD does not prevent IGF-
stimulated production of p21 or IGF-mediated myoblast
survival. A diagram outlining the interrelationships be-
tween these pathways is presented in Fig. 10.
It has been established in cultured muscle cells that p21
mRNA and protein expression increase dramatically with
the onset of differentiation (Guo et al., 1995; Halevy et al.,
1995; Parker et al., 1995), and that p21 contributes to the
cell cycle arrest and resistance to apoptosis that occur
early in differentiation (Andres and Walsh, 1996; Wang
and Walsh, 1996). Although p21 null mice do not demon-
strate abnormalities in skeletal muscle (Deng et al., 1995),
mice deficient in both p21 and the related cyclin-depen-
dent kinase inhibitor, p57, display marked defects in mus-
cle differentiation and exhibit increased myoblast apopto-
sis during embryonic development (Zhang et al., 1999).
These results confirm observations made with cultured
muscle cells, but illustrate the complexity and functional
redundancy within this family of cyclin-dependent kinase
inhibitors in vivo. Little p57 can be detected in C2 myo-
blasts (Zhang et al., 1999), thus explaining why abrogation
of p21 expression enhances cell death. A major function
for p21 (and presumably p57) in muscle cells is to promote
arrest in the G1 phase of the cell cycle by inhibiting activ-
ity of cyclin-dependent kinases, which otherwise would
phosphorylate and inactivate the retinoblastoma protein,
pRb (Elledge, 1996; Jacks and Weinberg, 1998). Active
pRb in turn restrains E2F transcription factors, thus
preventing induction of genes involved in cell-cycle pro-
gression (Weinberg, 1995). It remains to be established
whether this is also the mechanism by which p21 sustains
myoblast survival. Of interest, transgenic mice expressing
low levels of pRb in an otherwise pRb null background
have muscle defects similar to those of p21- and p57-defi-
cient mice (Zackenhaus et al., 1996).
It has been shown by several investigators that MyoD
induces p21 gene and protein expression in differentiating
myoblasts (Guo et al., 1995; Halevy et al., 1995; Parker et
al., 1995), in fibroblasts from intact and p53-deficient mice,
and in other cell types by transcriptional pathways (Ha-
levy et al., 1995) that are not dependent on ongoing pro-
tein synthesis (Otten et al., 1997), implying that MyoD
transactivates the p21 gene. Our results now define a
MyoD-independent mechanism for controlling p21 ex-
pression in muscle cells through an IGF-I–activated signal
transduction pathway involving PI3-kinase and Akt. Previ-
ously published experiments from others also may be in-
terpreted to support the idea that MyoD and p53 are not
the only factors regulating p21 expression in muscle. Dur-
ing embryonic development in mice, p21 mRNA is de-
tected in somites destined to form muscle at day 8.5 post
coital, a full 2 d before MyoD gene expression is measur-
able (Parker et al., 1995). In addition, p21 mRNA is equiv-
alently expressed in presumptive muscle in developing
wild-type mice and in mice lacking both MyoD and myo-
genin (Parker et al., 1995). It has not been established if
other myogenic basic helix-loop-helix transcription factors
are responsible for induction of p21 under these circum-
stances or whether additional pathways are involved, such
as those activated by the IGF-I receptor. Since IGF-II is
strongly expressed in the somites at day 8.5 post coital and
throughout muscle development in mice (Lee et al., 1990),
it is conceivable that IGF-mediated mechanisms contrib-
ute to MyoD-independent regulation of p21 expression
during embryonic development.
IGF-I receptor null mice also display muscle hypoplasia
(Liu et al., 1993), but it is not known whether the underly-
ing defect results from decreased proliferation of muscle
precursor cells or from increased apoptosis. In this report,
we define two IGF-I receptor-activated survival pathways
in cultured myoblasts that require PI3-kinase. A role for
PI3-kinase in muscle differentiation had been established
previously. Inhibition of kinase activity had been shown to
blunt differentiation (Kaliman et al., 1996, 1998; Coolican
et al., 1997; Jiang et al., 1998, 1999), and forced expression
of active enzyme had been found to enhance differentia-
Figure 10. Model for IGF-regulated muscle cell survival. Ligand-
induced activation of the IGF-I receptor (IGF-IR) leads to stim-
ulation of PI3-kinase enzymatic activity through the adapter mol-
ecules, IRS-1 and -2. PI3-kinase subsequently activates Akt,
which stimulates expression of p21 mRNA and protein, which
then promotes muscle cell survival. PI3-kinase through unidenti-
fied steps also stimulates expression of MyoD, which then in-
duces p21. MyoD plays a secondary role in the induction of p21
and in IGF-mediated cell survival.Lawlor and Rotwein Mechanisms of IGF–mediated Myoblast Survival 1139
tion (Jiang et al., 1998), although in no studies have the
downstream signaling pathways been delineated. We now
demonstrate that activation of PI3-kinase leads to induc-
tion of MyoD expression by a mechanism that does not ap-
pear to require Akt. Other downstream effectors of PI3-
kinase have been identified in several cell types, including
p70 S6 kinase, and atypical protein kinases C, d, and z
(Chou et al., 1998; Le Good et al., 1998; Pullen et al., 1998).
We have been unable to establish in preliminary experi-
ments a role for either p70 S6 kinase or protein kinase C z
in myoblast survival (data not shown). It also has been
found recently that PI3-kinase can induce the phosphoryla-
tion and enhance the activity of the MEF2 muscle tran-
scription factors (Tamir and Bengal, 2000), although this
has not been shown to be a direct effect, and it is not known
if MEF2 proteins contribute to muscle cell survival. Addi-
tional signaling molecules potentially involved in regulating
myoblast differentiation and downstream of PI3-kinase in-
clude members of the Rho family of small GTPases, RhoA,
Rac, and Cdc42 (Nobes and Hall, 1994). Inhibition of activ-
ity of these proteins, either through use of dominant inter-
fering mutants or overexpression of the GDP dissociation
inhibitor, RalGDI, can block expression of muscle-specific
genes and prevent differentiation (Carnac et al., 1998;
Ramocki et al., 1998; Takano et al., 1998; Wei et al., 1998).
To date, the Rho family has not been linked to muscle cell
survival pathways controlled by the IGF-I receptor.
The signaling pathways and mechanisms by which Akt
enhances p21 gene expression are similarly unknown. In
some cell types, Akt has been shown to activate the tran-
scription factor NF-kB by stimulating the kinases that
phosphorylate its inhibitor, IkB, and target it for destruc-
tion (Kane et al., 1999; Romashkova and Makarov, 1999;
Sizemore et al., 1999). Although NF-kB is expressed in C2
myoblasts (Kaliman et al., 1999), we have found that it is
not induced by IGF-I in these cells (Lawlor and Rotwein,
2000), thus making it unlikely to be involved in Akt-medi-
ated gene activation. Members of the p38 family of mito-
gen-activated protein (MAP) kinases have been demon-
strated to phosphorylate and activate MEF2 proteins
(Yang et al., 1999; Zhao et al., 1999), but p38 MAP kinases
are not activated by Akt and have not been found to stim-
ulate p21 gene expression or promote myoblast survival.
In summary, we have identified two distinct IGF-I re-
ceptor and PI3-kinase–activated signal transduction path-
ways that contribute to the maintenance of myoblast via-
bility through induction of p21. This dual mechanism of
p21 regulation may function to ensure the appropriate ex-
pression of this critical survival factor. It remains to be de-
termined whether similarly multilayered interdependent
pathways control p21 gene expression in vivo, where they
potentially may act to modulate myoblast viability and
muscle mass during embryonic and adult life.
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